With Resta­sis in its crosshairs, My­lan adds a Botox biosim with Re­vance; Ver­tex starts sec­ond PhI­II triple com­bo CF study

With My­lan $MYL al­ready mov­ing in for the kill with a gener­ic ver­sion of Al­ler­gan’s Resta­sis, the big gener­ics com­pa­ny has set up a new pro­gram that can al­so go af­ter Al­ler­gan’s multi­bil­lion-dol­lar fran­chise for Botox. My­lan to­day an­nounced a deal to part­ner with Re­vance Ther­a­peu­tics $RVNC on a short-act­ing knock­off of Botox, which pro­vid­ed Al­ler­gan with chart-top­ping rev­enue of $3.4 bil­lion last year. Re­vance is al­ready an­gling to grab a share of the Botox mar­ket with a late-stage long-act­ing ri­val, along with com­pe­ti­tion from Evo­lus and Hugel. And there have been mixed re­views of just how suc­cess­ful that might be.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.